Advertisement
U.S. markets closed

Inhibikase Therapeutics, Inc. (IKT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.1500-0.0100 (-0.46%)
At close: 04:00PM EST
2.1500 0.00 (0.00%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close2.1600
Open2.1800
Bid2.1300 x 1100
Ask2.2000 x 800
Day's Range2.0700 - 2.2199
52 Week Range0.7900 - 5.6100
Volume76,763
Avg. Volume191,310
Market Cap13.301M
Beta (5Y Monthly)1.34
PE Ratio (TTM)N/A
EPS (TTM)-3.9900
Earnings DateMar 29, 2024 - Apr 02, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for IKT

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Inhibikase Therapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 06/23/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    8 months agoArgus Research
View more
  • GlobeNewswire

    Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro

    Company to pursue eleven indications for IkT-001Pro; all previously approved for treatment with imatinib mesylateBOSTON and ATLANTA, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced preliminary outcomes of the

  • Zacks

    Here's Why Inhibikase Therapeutics, Inc. (IKT) Is a Great 'Buy the Bottom' Stock Now

    Inhibikase Therapeutics, Inc. (IKT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

  • Zacks

    New Strong Buy Stocks for February 13th

    IKT, ETRN, ADMA, AFRM and ORC have been added to the Zacks Rank #1 (Strong Buy) List on February 13, 2023.